<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-91e9c5c4=""><div class="content_outer_container" data-v-91e9c5c4=""><div class="share_preview_container" data-v-91e9c5c4=""><div class="dialog_list" data-v-91e9c5c4=""><div class="dialog_item" data-v-91e9c5c4=""><div class="dialog_question fir_dialog_question" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""><h1 class="fir_question_content" data-v-91e9c5c4="">
                                    How did Vertex Pharmaceuticals' revenue and expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-91e9c5c4=""> <span class="user_desction" data-v-91e9c5c4="">
                                        
                                        5/7/2025 04:25pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-91e9c5c4="">Vertex Pharmaceuticals experienced a decrease in advertising and marketing expenses by 10.03% to $450.03 million, while R&amp;D expenses remained stable at $998.7 million. The company's revenue was $11.02 billion, with TRIKAFTA and its related products contributing significantly.


</div> <div class="dialog_answer" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""> <div class="answer_robot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/AIme.ae832fb.png" alt="robot" class="avatar" data-v-91e9c5c4=""> <div class="user_name" data-v-91e9c5c4=""></div></div> <div class="question_content" data-v-91e9c5c4=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-4e97ba8a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-4e97ba8a=""> <div class="recommend-part" data-v-7790c618="" data-v-4e97ba8a=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad){return {layout:"default",data:[{noData:c,currentQuestion:f,textDescription:E,comeFrom:"AInvestShareLink",events:[],answerSource:q}],fetch:{},error:i,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:j,agent_id:a,output_media_info:[],task_id:a,language:a,source:q,cache_builder:a,reply_action:"Answer",execute_mode:x,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Vertex Pharmaceuticals' revenue and expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Vertex Pharmaceuticals' revenue and expenses trend in Q4 2024?\",\"user_id\":\"dp29937380\",\"user_name\":\"\",\"trace_id\":\"b5703eb9-a9a6-4f2d-93ce-09d50db68d68\",\"session_id\":\"b5703eb9-a9a6-4f2d-93ce-09d50db68d68\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:y,text:"11 results found:\n|Advertising and Marketing Expenses[20241231]|Last Change|Last Price|R&D Expenses[20241231]|Report End Date|Revenue by Segment[20241231]|Segment Basis|Segment Name|stock code|stock name|\n|---|---|---|---|---|---|---|---|---|---|\n||-10.03%|$450.03|$998.7 million|20241231|11.02 billion|Business|Product|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|10.24 billion|Business|TRIKAFTA|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|8.11 billion|Business|Product|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|7.52 billion|Business|TRIKAFTA|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|2.76 billion|Business|Product|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|2.54 billion|Business|TRIKAFTA|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|781.5 million|Business|Other Product Revenues|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|590.3 million|Business|Other Product Revenues|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|170.8 million|Business|Other Product Revenues|VRTX|Vertex Pharmaceuticals|\n||-10.03%|$450.03|$998.7 million|20241231|53.9 million|Business|ALYFTREK|VRTX|Vertex Pharmaceuticals|\n",query_data:{number:j,title:z,query_type:y,condition:a,model_sql:F,data_ext_params:{merge_repeat:c,expand_index:b,data_add:j,add_index:e}}}],answer_chain_name:G,agent_mode:H,native_answer:a,come_from:a,text_answer:E,trace_id:k,cost:17430,event_names:a,question:f,fallback_type:I,input_type:"typewrite",fall_back_reason:{fall_back_type:I,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:k,first_return_cost:3546,cache_type:"no_cache",question_id:k,transfer_question:f,signal_type:"ON_COMPLETE",start_time:J,remote_svc:q,slots:[],answer_type:x,user_id:A,skill_name:B},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:k,session_id:k,user_id:A,question:f,source:q,raw_question:f,version:"3.4.1",action_name:B,nlu:{entity:[{type:K,value:"VRTX.O",market:L}]},deep_research:c,deep_thinking:c,agent_mode:H},extra:{}},{answer_path:r,section:{id:s,info_texts:["Thinking"],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:r,section:{id:s,info_texts:["Querying Stock: VRTX Revenue by Business, R&D Expenses, Sales and Marketing Expenses in Q4 2024"],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:z,thought:"The user seeks to analyze Vertex Pharmaceuticals' (VRTX) revenue and expense trends in Q4 2024. I should focus on VRTX's Q4 2024 revenue, R&D expenses, and sales and marketing expenses data. I will use FinQuery for the data mentioned above."}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:r,section:{id:s,info_texts:["Generating Answer"],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:u,info_texts:[],show_type:v,voice_txt:"Vertex",text_answer:M,rich_text:M,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:v,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:z,query_type:y,trace_data:a,index:j,model_sql:F,data_ext_params:{merge_repeat:c,expand_index:b,data_add:j,add_index:e},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:u,info_texts:[],show_type:v,voice_txt:". The",text_answer:N,rich_text:N,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"VRTX",market_id:L,name:O,domain:K},pos:e,section_id:u,txt:O,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:u,info_texts:[],show_type:v,voice_txt:"\n",text_answer:P,rich_text:P,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:r,section:{id:s,info_texts:["Completed"],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:m,query_text:m,trace_info:{item_id:"de8c4043917321561f142570910c7235",item_type:h,item_name:m,rec_info:Q}},{display_text:n,query_text:n,trace_info:{item_id:"e16940f395c277d29b4919308639cbaf",item_type:h,item_name:n,rec_info:R}},{display_text:o,query_text:o,trace_info:{item_id:"a014c456c8544c769aa1462d75ff07ce",item_type:h,item_name:o,rec_info:S}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:e,type:"1",display2:c,url:a}},request_config:[{source_type:T,related_name:U}],puuid:C,tag:a,category:"custom",uuid:V}],global:{urp_static_data:[{name:U,value:{status_code:e,columns:[{type:p,index_name:W,key:W},{type:p,index_name:X,key:X},{type:p,index_name:Y,key:Y},{type:p,index_name:Z,key:Z},{type:p,index_name:_,key:_}],datas:[{send_text:m,item_type:h,rec_info:Q,display_text:m,rec_reason:a},{send_text:n,item_type:h,rec_info:R,display_text:n,rec_reason:a},{send_text:o,item_type:h,rec_info:S,display_text:o,rec_reason:a}],dataSize:T,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:$,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:w,"min-height":"100%",position:aa,height:w},isMaterial:c,id:$,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:D,componentUuid:V,script:[{name:ab,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:D,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:D},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:w,position:aa,height:w},isMaterial:b,_id:19,id:ab,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ac,voice_txt:a,tracking_info:{},uuid:C},order:{is_auto:c,render_for:ac,chart_type:"command",puuid:C}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:B,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:x,answer_chain_name:G},is_deep_research:c,deep_thinking:c,create_time:1746606328262},is_last:b}],questionItem:{data:{qStr:f,encodeFlag:c,imageData:i,docsData:[],quoteData:i},tplType:"question"},events:[],agentId:a}],userId:A,userName:a,startTime:J,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:i,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],traceTableData:i,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-vertex-pharmaceuticals-revenue-and-expenses-trend-in-q4-2024-1ccc6e\u002F",config:{_app:{basePath:ad,assetsPath:ad,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer",0,"How did Vertex Pharmaceuticals' revenue and expenses trend in Q4 2024?","signal","llm_generated",null,1,"b5703eb9-a9a6-4f2d-93ce-09d50db68d68",999,"What were Vertex Pharmaceuticals' revenue figures for Q4 2024?","What were the key drivers of Vertex Pharmaceuticals' revenue growth in Q4 2024?","Did Vertex Pharmaceuticals report any significant one-time expenses in Q4 2024?","STR","ths_ainvest_lite_web","progress\u002Fsearching_for",1000,"searching_for",2001,"rich_text","auto","agent","intusstock","VRTX Revenue by Business, R&D Expenses, Sales and Marketing Expenses in Q4 2024","dp29937380","inspect stocks","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Vertex Pharmaceuticals experienced a decrease in advertising and marketing expenses by 10.03% to $450.03 million, while R&D expenses remained stable at $998.7 million. The company's revenue was $11.02 billion, with TRIKAFTA and its related products contributing significantly.\n\n\n","select   stock_code,   revenue_by_segment from   ustock_rev_comp where   report_end_date = date('2024y4q')   and stock_code = 'VRTX.O'   and segment_basis = 'business' intersect select   stock_code,   r_d_expenses,   advertising_and_marketing_expenses from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'VRTX.O'","agent_common_v2\nagent-summary","normal_agent","NONE",1746606310832,"stock","185","Vertex Pharmaceuticals experienced a decrease in advertising and marketing expenses by 10.03% to $450.03 million, while R&D expenses remained stable at $998.7 million[^1]",". The company's revenue was $11.02 billion, with TRIKAFTA and its related products contributing significantly.\n\n","Vertex Pharmaceuticals","\n``` visual\n{\"uuid\":\"e4172f93-84aa-441d-bba9-fff36f98112d\"}\n```","2+679_496_21_554+0+0+b5703eb9-a9a6-4f2d-93ce-09d50db68d68+de8c4043917321561f142570910c7235+llm_generated+aimeTagAnalysis+0+0.08986799418926239+1","2+679_496_21_554+0+0+b5703eb9-a9a6-4f2d-93ce-09d50db68d68+e16940f395c277d29b4919308639cbaf+llm_generated+aimeTagAnalysis+0+0.044267572462558746+2","2+679_496_21_554+0+0+b5703eb9-a9a6-4f2d-93ce-09d50db68d68+a014c456c8544c769aa1462d75ff07ce+llm_generated+aimeTagAnalysis+0+0.04329652711749077+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/195837b.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/e402278.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7c15041.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/69a864a.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/9579193.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/6726d3c.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/c69ce63.js" defer=""></script>